<DOC>
	<DOCNO>NCT01316549</DOCNO>
	<brief_summary>Fludarabine chemotherapy drug use extensively bone marrow transplantation . The goal study determine cause child different drug concentration fludarabine body drug level relate whether child experience severe side-effects bone marrow transplant . The hypothesis clinical genetic factor cause change fludarabine drug level pediatric bone marrow transplant patient high level may cause severe side-effects .</brief_summary>
	<brief_title>Study Fludarabine Drug Exposure Pediatric Bone Marrow Transplantation</brief_title>
	<detailed_description>Fludarabine nucleoside analog potent antitumor immunosuppressive property use condition regimen pediatric allogeneic hematopoietic cell transplantation ( alloHCT ) promote stem cell engraftment . This single-center , pharmacokinetic-pharmacodynamic ( PK-PD ) study investigate clinical pharmacology fludarabine 45 child undergo alloHCT UCSF Benioff Children 's Hospital . Patients would receive fludarabine regardless whether decide consent PK sampling . Fludarabine dose adjust base PK data . We apply combination D-optimality-based limited sampling strategy population PK methodology determine specific factor influence fludarabine exposure pediatric alloHCT recipient identify exposure-response relationship . Subjects undergo PK sample plasma ( f-ara-a ) intracellular ( f-ara-ATP ) drug concentration duration fludarabine therapy ( 3 5 day ) . To evaluate source variability impact fludarabine exposure clinical data obtain patient 's medical chart day PK sampling . A single blood draw collection DNA genotyping single nucleotide polymorphism gene involve fludarabine activation , transport elimination occur patient . To assess exposure-response relationship neutrophil engraftment , treatment-related toxicity , survival data collect day 100 post-transplant .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>Hemoglobinopathies</mesh_term>
	<mesh_term>Fanconi Anemia</mesh_term>
	<mesh_term>Fanconi Syndrome</mesh_term>
	<mesh_term>Metabolism , Inborn Errors</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<criteria>Children 017 year age Undergoing alloHCT treatment malignant nonmalignant disorder Receiving fludarabinebased preparative regimen Any child 717 year age unwilling provide assent Parent guardian unwilling provide write consent</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>fludarabine</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>pediatric</keyword>
	<keyword>allogeneic</keyword>
	<keyword>hematopoietic cell transplantation</keyword>
</DOC>